Q-omics provides the consensus-scored MIR151A profile across patient tissues and cancer cell-line models. MIR151A expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR151A is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR151A RNA expression shows 6,935 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, BRCA, and GBM as cancer lineages where MIR151A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR151A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR151A survival associations across molecular data types. MIR151A RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR151A RNA expression–survival associations across cancer types. High MIR151A expression shows unfavorable associations in CESC, READ, KIRC, SKCM, PAAD and OV. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for MIR151A RNA expression.
This table summarizes MIR151A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR151A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR151A shows higher tumor expression in BRCA, LUSC and LUAD. The BRCA box plot shows higher MIR151A RNA expression in tumor versus normal tissue (log2 FC = +0.196, t-test p = .033).
This table shows molecular features associated with MIR151A in patient tissues and cancer cell lines. In patient samples, MIR151A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
